ReviewFrontiers in cellular neuroscience2019
Local Drug Delivery for the Treatment of Neurotology Disorders.
Review in Frontiers in cellular neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- High-Precision 3D Printing of Microporous Cochlear Implants for Personalized Local Drug Delivery.Journal of functional biomaterials · 2023Article
- Intranasal delivery of NGF rescues hearing impairment in aged SAMP8 mice.Cell death & disease · 2023Article
- Injectable Poloxamer Hydrogel Formulations for Intratympanic Delivery of Dexamethasone.Journal of Korean medical science · 2023Article
- Local Delivery of Therapeutics to the Cochlea Using Nanoparticles and Other Biomaterials.Pharmaceuticals (Basel, Switzerland) · 2022Review
- An Evaluation of the Drug Permeability Properties of Human Cadaveric In Situ Tympanic and Round Window Membranes.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Hearing loss: The final frontier of pharmacology.Pharmacology research & perspectives · 2022Review
- Encapsulation of Alpha-Lipoic Acid in Functional Hybrid Liposomes: Promising Tool for the Reduction of Cisplatin-Induced Ototoxicity.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Protection of Hearing Loss in Ototoxic Mouse Model Through SPIONs and Dexamethasone-Loaded PLGA Nanoparticle Delivery by Magnetic Attraction.International journal of nanomedicine · 2022Article
- Nanoparticles for the Treatment of Inner Ear Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- An injectable PEG hydrogel controlling neurotrophin-3 release by affinity peptides.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Robotic Milling of Electrode Lead Channels During Cochlear Implantation in anFrontiers in surgery · 2021Article
- Multidisciplinary Tinnitus Research: Challenges and Future Directions From the Perspective of Early Stage Researchers.Frontiers in aging neuroscience · 2021Review
- Direct Delivery of Antisense Oligonucleotides to the Middle and Inner Ear Improves Hearing and Balance in Usher Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Microtechnologies for inner ear drug delivery.Current opinion in otolaryngology & head and neck surgery · 2020Review
- Ultrastructural Changes Associated With the Enhanced Permeability of the Round Window Membrane Mediated by Ultrasound Microbubbles.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotology disorders such as vertigo, tinnitus, and hearing loss affect a significant proportion of the population (estimated 39 million in the United States with moderate to severe symptoms). Yet no pharmacological treatments have been developed, in part due to limitations in effective drug delivery to the anatomically protected inner ear compartment. Intratympanic delivery, a minimally invasive injection performed in the office setting, offers a potential direct route of administration. Currently, off-label use of therapeutics approved to treat disorders via systemic administration are being injected intratympanically, mostly in the form of aqueous solutions, but provide variable levels of drug exposure for a limited time requiring repeated injections. Hence, current drug delivery approaches for neurotology disorders are sub-optimal. This review, following a description of pharmacokinetic considerations of the inner ear, explores the merits of novel delivery approaches toward the treatment of neurotology disorders. Methodologies employing local delivery to the inner ear are described, including direct intracochlear delivery as well as intratympanic methods of infusion and injection. Intratympanic injection delivery formulation strategies including hydrogels, polymers and nanoparticulate systems are explored. These approaches represent progress toward more effective delivery options for the clinical treatment of a variety of neurotology disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.